| Autor: |
Muharrem, Kocar, Emine, Bozkurtlar, Ferhat, Telli, Fulden, Yumuk, Handan, Kaya, Hande, Kocar, Nazim, Serdar Turhal |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 19(1) |
| ISSN: |
1107-0625 |
| Popis: |
Unraveling the mechanisms underlying the resistance to trastuzumab is important for amending the prognosis of patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Experimentally, it has been shown that p95-HER2 positive breast tumors are resistant to trastuzumab. The aim of this study was to investigate the predictive and prognostic importance of p95-HER2 expression by immunohistochemistry in HER2-positive metastatic breast cancer patients treated with trastuzumab.Only patients who had a histological diagnosis of HER2-positive metastatic breast cancer and who had received first line therapy containing trastuzumab were enrolled in the study. Immunohistochemistry was used to analyze p95-HER2 expression in the tissue blocks of the patients.The study was performed on 38 patients aged between 30 and 84 years. In 14 patients (36.8%), p95-HER2 was positive, whereas it was negative in the remaining 24 patients (63.2%). There was no significant correlation between p95-HER2 expression and overall survival, response to trastuzumab, and progression-free survival (PFS).Unlike previous reports, there was no correlation between the p95-HER2 expression and resistance to trastuzumab. It may be argued that an analysis using immunohistochemistry is inadequate for determining p95- HER2. In order to ascertain whether immunohistochemistry is an appropriate method, studies with larger patient groups are needed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
